Delivery Order SPE2DB22D2206-SPE2DB25FJK83
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,575.75 for IMBRUVICA 140 mg tablets (28-count supply) on August 28, 2025, with completion scheduled for September 19, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of IMBRUVICA 420 mg tablets (28-count packages) with a ceiling value of $15,151.52. This is a firm fixed-price delivery order with an ultimate completion date of October 1, 2025, and carries no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $50,797.65 delivery order by the Defense Logistics Agency on May 12, 2025, for the supply of IMBRUVICA 420 mg tablets (28-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025. The award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $15,151.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 280 mg tablets (28 count) on June 6, 2025, with completion targeted for June 30, 2025. This non-competitive, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1 billion through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) with delivery to Conshohocken, Pennsylvania. This contract, awarded on August 4, 2025, utilizes a firm fixed-price structure with an ultimate completion date of August 25, 2025. The award was made without a set-aside designation, indicating it was competitively awarded among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of IMBRUVICA 140 mg capsules (90-count units) with a ceiling value of $16,233.74. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $15,151.52 on August 15, 2025, for the supply of Imbruvica 280 mg tablets (quantity: 28 units) under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The order is non-set-aside and competitively awarded, with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJK83Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $37,878.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical supplier to military and veteran healthcare systems. The SPE2DX IDC functions as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide. This delivery order for IMBRUVICA, a specialized pharmaceutical product, exemplifies the company's role in fulfilling critical medical supply needs across multiple therapeutic domains for federal procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.9k | 8/14/25 |